NCT05548296 2026-01-22A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaAcrivon TherapeuticsPhase 2 Recruiting353 enrolled
NCT02203513 2022-09-10A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerNational Institutes of Health Clinical Center (CC)Phase 2 Terminated111 enrolled 15 charts